Mediar Therapeutics has dosed the first subject in the Phase II WISPer trial of its investigational therapy, MTX-463, for IPF ...

The trial is designed to evaluate this human immunoglobulin G1 (IgG1) antibody, which targets WNT1-inducible signalling pathway protein-1 (WISP1), a matricellular protein implicated in the ...

For example, matricellular proteins such as CCN4 (WISP1) have been shown to modulate cellular communication and influence cell survival mechanisms. Concurrently, signalling cascades related to ...

Main Camera Triple 12 MP, f/1.7, 24mm (wide), 1/1.7", 1.8µm, dual pixel PDAF, OIS 12 MP, f/2.3, 85mm (telephoto), f/2.8, 125mm (telephoto), 1/3.5", dual pixel PDAF ...

U.S. 3 Year Treasury Note 0.1320 3.9810% U.S. 5 Year Treasury Note 0.0140 4.0840% U.S. 7 Year Treasury Note 0.0170 4.2660% ...

U.S. 3 Year Treasury Note 0.022 3.967% U.S. 5 Year Treasury Note 0.022 4.066% U.S. 7 Year Treasury Note 0.046 4.254% ...

Editorial Note: The Coingape Marketing Editor Team provided a neutral viewpoint when creating the content. Though we receive commission for sponsored additions, this has no bearing on our assessments ...